T\u00fcbingen\/Geleen (NL) \u2014 SHS Capi\u00adtal has signed a binding agree\u00adment to acquire a majo\u00adrity stake in Basic Pharma Holding B.V., a Nether\u00adlands-based phar\u00admaceu\u00adti\u00adcal deve\u00adlo\u00adper and full-service CDMO (contract deve\u00adlo\u00adp\u00adment and manu\u00adfac\u00adtu\u00adring orga\u00adniza\u00adtion). The tran\u00adsac\u00adtion is expec\u00adted to close shortly. <\/p>\n
Basic Pharma<\/strong> is a specia\u00adli\u00adzed deve\u00adlo\u00adper and manu\u00adfac\u00adtu\u00adrer of nasal sprays and semiso\u00adlid phar\u00admaceu\u00adti\u00adcals. The inte\u00adgra\u00adted \u201cLicense & Supply\u201d model\u2014which combi\u00adnes in-house product deve\u00adlo\u00adp\u00adment, proprie\u00adtary dossiers, regu\u00adla\u00adtory affairs, phar\u00adma\u00adco\u00advi\u00adgi\u00adlance, and GMP manufacturing\u2014sets the company apart in the Euro\u00adpean market; in terms of produc\u00adtion capa\u00adcity, Basic Pharma ranks among the leading Euro\u00adpean nasal spray CDMOs. <\/p>\n The company has grown signi\u00adfi\u00adcantly in recent years, driven by strong demand for its nasal sprays, creams, and newly laun\u00adched prescrip\u00adtion products, and bene\u00adfits from a very loyal custo\u00admer base consis\u00adting of white-label and private-label distri\u00adbu\u00adtors as well as gene\u00adric drug companies.<\/p>\n Succes\u00adsion Plan for the Founders Foun\u00added in 2003 by phar\u00admacist Bob Kool, Basic Pharma<\/strong> has evol\u00adved from a local contract manu\u00adfac\u00adtu\u00adrer into an inte\u00adgra\u00adted phar\u00admaceu\u00adti\u00adcal plat\u00adform that combi\u00adnes in-house product deve\u00adlo\u00adp\u00adment, regu\u00adla\u00adtory affairs, phar\u00adma\u00adco\u00advi\u00adgi\u00adlance, and GMP manu\u00adfac\u00adtu\u00adring at its site in Geleen, the Nether\u00adlands, and serves an inter\u00adna\u00adtio\u00adnal custo\u00admer base across prescrip\u00adtion (Rx) and over-the-coun\u00adter (OTC) drugs as well as inves\u00adti\u00adga\u00adtio\u00adnal products. A key diffe\u00adren\u00adtia\u00adtor is the company\u2019s ability to deve\u00adlop, regis\u00adter, and out-license product dossiers: Under the \u201cLicense & Supply\u201d model, intern\u00adally deve\u00adlo\u00adped products are licen\u00adsed to distri\u00adbu\u00adtors and phar\u00admaceu\u00adti\u00adcal part\u00adners, while Basic Pharma reta\u00adins exclu\u00adsive manu\u00adfac\u00adtu\u00adring and dossier rights. This fosters long-term custo\u00admer rela\u00adti\u00adonships and strong recur\u00adring reve\u00adnue. Basic Pharma holds a leading posi\u00adtion in the Dutch nasal spray market and, thanks to a lean and highly effi\u00adci\u00adent produc\u00adtion struc\u00adture, offers its products at compe\u00adti\u00adtive prices, inclu\u00adding internationally. <\/p>\n SHS Capi\u00adtal intends to support Basic Pharma as a growth part\u00adner in the coming years. The joint value-crea\u00adtion plan focu\u00adses on streng\u00adthening the highly successful core busi\u00adness, enhan\u00adcing opera\u00adtio\u00adnal excel\u00adlence, profes\u00adsio\u00adna\u00adli\u00adzing the orga\u00adniza\u00adtion, and acce\u00adle\u00adra\u00adting inter\u00adna\u00adtio\u00adnal expan\u00adsion, parti\u00adcu\u00adlarly in Euro\u00adpean markets with attrac\u00adtive pricing dyna\u00admics. Further\u00admore, Basic Pharma is well-posi\u00adtio\u00adned as a plat\u00adform for selec\u00adtive buy-and-build tran\u00adsac\u00adtions in the frag\u00admen\u00adted Euro\u00adpean CDMO land\u00adscape. Foun\u00adder Bob Kool will conti\u00adnue to support the company and remain asso\u00adcia\u00adted with it as a share\u00adhol\u00adder and member of the advi\u00adsory board. <\/p>\n \u201cOver more than two deca\u00addes, we have built Basic Pharma into an inte\u00adgra\u00adted phar\u00admaceu\u00adti\u00adcal plat\u00adform with a strong team and loyal, long-stan\u00adding custo\u00admers,\u201d says Bob Kool, foun\u00adder and CEO of Basic Pharma<\/strong>. \u201cIt was very important to me to place the future of my life\u2019s work in the right hands. In SHS, we have found an extre\u00admely expe\u00adri\u00aden\u00adced and specia\u00adli\u00adzed health\u00adcare private equity fund that truly under\u00adstands our busi\u00adness, values our employees, and shares our ambi\u00adti\u00adons. I am very plea\u00adsed that the next chap\u00adter of Basic Pharma will be writ\u00adten toge\u00adther with such a compe\u00adtent part\u00adner, and I look forward to conti\u00adnuing to support the company during this exci\u00adting phase.\u201d <\/p>\n \u201cBasic Pharma is exactly the kind of company we\u2019re looking for: a specia\u00adli\u00adzed Euro\u00adpean health\u00adcare cham\u00adpion with a diffe\u00adren\u00adtia\u00adted busi\u00adness model, its own drug candi\u00adda\u00adtes, and signi\u00adfi\u00adcant, untap\u00adped inter\u00adna\u00adtio\u00adnal poten\u00adtial,\u201d says Dr. Corne\u00adlius Maas, a part\u00adner at SHS Capi\u00adtal<\/strong>. \u201cWe look forward to support\u00ading the team in the next phase of growth\u2014both orga\u00adni\u00adcally and through selec\u00adtive acquisitions.\u201d <\/p>\n About Basic Pharma<\/strong><\/p>\n Basic Pharma Holding B.V. is a Nether\u00adlands-based phar\u00admaceu\u00adti\u00adcal deve\u00adlo\u00adper and full-service CDMO compri\u00adsing Basic Pharma Manu\u00adfac\u00adtu\u00adring, Basic Pharma Tech\u00adno\u00adlo\u00adgies, and Inter\u00addos Pharma. The company deve\u00adlops, regis\u00adters, and manu\u00adfac\u00adtures prescrip\u00adtion and over-the-coun\u00adter (OTC) medications\u2014including nasal sprays, creams, oint\u00adments, liquid dosage forms, and pre-filled syringes\u2014as well as inves\u00adti\u00adga\u00adtio\u00adnal drugs for clini\u00adcal trials. Through Inter\u00addos Pharma, the group also provi\u00addes services in the areas of regu\u00adla\u00adtory affairs, phar\u00adma\u00adco\u00advi\u00adgi\u00adlance, QA\/QC, and Quali\u00adfied Person for both inter\u00adnal and exter\u00adnal clients. All products are manu\u00adfac\u00adtu\u00adred at the company\u2019s GMP-certi\u00adfied faci\u00adlity in Geleen (Nether\u00adlands). Basic Pharma employs more than 250 people and serves an inter\u00adna\u00adtio\u00adnal custo\u00admer base of distri\u00adbu\u00adtors and phar\u00admaceu\u00adti\u00adcal compa\u00adnies throug\u00adhout Europe. \u2014 https:\/\/basicpharma.nl\/ <\/p>\n About SHS Capital<\/strong><\/p>\n SHS Capi\u00adtal is a private equity firm foun\u00added in 1993 that invests in health\u00adcare compa\u00adnies in Europe. Its invest\u00adments focus on expan\u00adsion finan\u00adcing, chan\u00adges in owner\u00adship, and succes\u00adsion plan\u00adning. \u201cBuil\u00adding Euro\u00adpean Health\u00adcare Cham\u00adpi\u00adons\u201d is the invest\u00adment philo\u00adso\u00adphy that guides SHS in finan\u00adcing and deve\u00adlo\u00adping its port\u00adfo\u00adlio compa\u00adnies. The T\u00fcbin\u00adgen-based inves\u00adtor takes both mino\u00adrity and majo\u00adrity stakes. The natio\u00adnal and inter\u00adna\u00adtio\u00adnal inves\u00adtors in the SHS funds include pension funds, fund-of-funds, foun\u00adda\u00adti\u00adons, family offices, stra\u00adte\u00adgic inves\u00adtors, entre\u00adpre\u00adneurs, and the SHS manage\u00adment team. The AIF\u2019s equity or equity-like invest\u00adment amounts to up to \u20ac50 million. Volu\u00admes excee\u00adding this amount can be reali\u00adzed through a network of co-inves\u00adtors. In its invest\u00adment decis\u00adi\u00adons, SHS places great empha\u00adsis on ESG conside\u00adra\u00adti\u00adons and is ther\u00ade\u00adfore commit\u00adted to the UN PRI guide\u00adlines. \u2014 http:\/\/www.shs-capital.eu<\/p>\n","protected":false},"excerpt":{"rendered":" T\u00fcbingen\/Geleen (NL) \u2014 SHS Capi\u00adtal has signed a binding agree\u00adment to acquire a majo\u00adrity stake in Basic Pharma Holding B.V., a Nether\u00ad\u00adlands-based phar\u00admaceu\u00adti\u00adcal deve\u00adlo\u00adper and full-service CDMO (contract deve\u00adlo\u00adp\u00adment and manu\u00adfac\u00adtu\u00adring orga\u00adniza\u00adtion). The tran\u00adsac\u00adtion is expec\u00adted to close shortly. Basic Pharma is a specia\u00adli\u00adzed deve\u00adlo\u00adper and manu\u00adfac\u00adtu\u00adrer of nasal sprays and semiso\u00adlid phar\u00admaceu\u00adti\u00adcals. The integrated [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":60601,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[1366],"tags":[],"class_list":["post-60603","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en"],"yoast_head":"\n
\n<\/strong>
\n The invest\u00adment by SHS Capi\u00adtal provi\u00addes a struc\u00adtu\u00adred succes\u00adsion plan for foun\u00adder and CEO Bob Kool, who is reinves\u00adt\u00ading along\u00adside SHS Capi\u00adtal, and aims to acce\u00adle\u00adrate Basic Pharma\u2019s next phase of growth through inter\u00adna\u00adtio\u00adnal expan\u00adsion, conti\u00adnuous product deve\u00adlo\u00adp\u00adment, and selec\u00adtive buy-and-build transactions.<\/p>\n